https://www.trinidadtobagowellnesstoday.com/article/906931891-cronos-group-inc-to-hold-2026-first-quarter-earnings-conference-call-on-may-11-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:30:00+00:00 Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026 https://ml.globenewswire.com/media/68e2d88b-b8e0-404a-995d-415a33773982/small/cronos-wm-black-logo-2-2-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932300-palvella-therapeutics-to-present-qtorin-rapamycin-results-from-phase-3-selva-and-phase-2-toiva-studies-at-the-international-society-for-the-study-of Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:30:00+00:00 Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932304-briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:30:00+00:00 BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting https://ml.globenewswire.com/media/6fd3be2a-b6a2-4f35-a39c-dfd88259d9d0/small/briacell-logo-square-a-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932351-biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-greater-china-region Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:30:00+00:00 Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932305-kraig-biocraft-laboratories-advances-record-production-and-begins-processing-1-8-metric-tons-of-recombinant-spider-silk-cocoons Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:05:00+00:00 Kraig Biocraft Laboratories Advances Record Production and Begins Processing 1.8 Metric Tons of Recombinant Spider Silk Cocoons https://ml.globenewswire.com/media/94451402-ffdd-4e78-b266-aeb3e0d7bb22/medium/jon-rice-kblbs-coo-pictured-with-less-than-4-of-the-companys.jpg https://www.trinidadtobagowellnesstoday.com/article/906932218-pasithea-therapeutics-announces-grant-of-rare-pediatric-disease-designation-rpdd-by-fda-to-pas-004-for-treatment-of-neurofibromatosis-type-1-nf1 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:01:00+00:00 Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) https://ml.globenewswire.com/media/0016f128-13c3-45a7-8455-cec1f4768995/small/pasithealogo-png.png https://www.trinidadtobagowellnesstoday.com/article/906932225-invivyd-announces-chairman-marc-elia-to-speak-at-politico-health-care-summit Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:01:00+00:00 Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.trinidadtobagowellnesstoday.com/article/906931864-radiopharm-theranostics-presents-initial-findings-from-phase-1-first-in-human-heat-clinical-trial-for-177lu-rad202-in-her2-solid-tumors-at-american Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906931872-sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical-officer Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png https://www.trinidadtobagowellnesstoday.com/article/906931895-soleo-health-expands-rare-disease-capabilities-with-launch-of-soleorare-a-specialty-pharmacy-focused-on-complex-patient-needs Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.trinidadtobagowellnesstoday.com/article/906931981-seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906932066-passage-bio-reports-updated-interim-data-from-uplift-d-trial-and-provides-regulatory-and-corporate-updates Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates https://ml.globenewswire.com/media/b5b65eab-3831-4f38-a1e8-b9f8d9f028d7/small/logo-1-jpg.JPG https://www.trinidadtobagowellnesstoday.com/article/906932228-netramark-comments-on-u-s-executive-order-to-accelerate-treatments-for-serious-mental-illness-and-highlights-the-need-for-regulatory-grade-trial Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development https://ml.globenewswire.com/media/d65cf3f8-cf9c-475c-b740-09a659269da4/small/netramark-word-eye-blk-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932245-monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-cancer-research-aacr-annual-meeting-2026-on-the-potential-of-its Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors https://ml.globenewswire.com/media/20ed9999-454a-4e2a-aabc-217270a87d2d/small/mrtx-logo-primaryblue-4cp-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932307-nrx-pharmaceuticals-nasdaq-nrxp-welcomes-presidential-initiative-to-accelerate-approval-of-psychedelic-medications-to-treat-depression-ptsd-and Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.trinidadtobagowellnesstoday.com/article/906932314-conavi-medical-announces-fda-510-k-clearance-of-its-next-generation-hybrid-ivus-oct-system-for-intravascular-imaging Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging https://ml.globenewswire.com/media/4a28f1c0-f99d-4940-b2a7-201ab98cdaff/small/conavi-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906932319-seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T11:00:00+00:00 Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906927423-ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-pimozide-tablets-with-180-day-cgt-exclusivity Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:50:00+00:00 ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906927583-evidence-supporting-combined-use-of-deucrictibant-ir-with-deucrictibant-xr-presented-at-ciic-spring-2026-conference Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:50:00+00:00 Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906927640-silo-pharma-positioned-to-advance-treatment-targeting-ptsd-as-president-trump-signs-executive-order-aimed-at-accelerating-research-and-treatment-based Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:34:00+00:00 Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906927646-prelude-therapeutics-announces-pricing-of-90-0-million-underwritten-offering Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:30:00+00:00 Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering https://ml.globenewswire.com/media/cab62748-b61a-42cb-b552-b0c6c91c4e83/small/ptx-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906922925-kfsh-joins-c3-davos-of-healthcare-2026-in-sunnyvale-california-as-a-global-strategic-partner Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:12:35+00:00 KFSH Joins C3 Davos of Healthcare™ 2026 in Sunnyvale, California, as a Global Strategic Partner https://ml.globenewswire.com/media/9f73a943-28c0-4ee7-a796-2407051abbe7/small/logo-kfshrc-png.png https://www.trinidadtobagowellnesstoday.com/article/906922856-biodesix-to-report-first-quarter-2026-financial-results-on-may-4-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:00:00+00:00 Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026 https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.trinidadtobagowellnesstoday.com/article/906922873-prelude-therapeutics-presents-preclinical-data-from-development-candidate-prt13722-a-first-in-class-orally-bioavailable-potent-and-highly Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:00:00+00:00 Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 https://ml.globenewswire.com/media/cab62748-b61a-42cb-b552-b0c6c91c4e83/small/ptx-logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906922975-greenwich-lifesciences-presents-flamingo-01-phase-iii-trial-open-label-data-published-at-aacr-meeting-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T10:00:00+00:00 Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906909326-oculis-announces-completion-of-last-patient-visit-in-phase-3-diamond-program-with-ocs-01-eye-drops-for-the-treatment-of-diabetic-macular-edema Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T08:00:00+00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906895910-nxera-pharma-to-receive-us-10-million-milestone-payment-from-abbvie-under-collaboration-targeting-neurological-diseases Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T06:30:00+00:00 Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases https://ml-eu.globenewswire.com/media/5cc74d52-c86f-4e21-8684-3496281fee15/small/nxera-master-logo-rgb-black-1-png.png https://www.trinidadtobagowellnesstoday.com/article/906895935-nanobiotix-annonce-de-nouvelles-donn-es-pr-cliniques-d-montrant-une-am-lioration-de-la-biodisponibilit-syst-mique-et-la-r-duction-de-la-toxicit-pour Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de… https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906896055-nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906891437-reminder-last-exercise-day-for-nicox-june-2024-warrants-is-june-19-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T05:30:00+00:00 Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/logo-png.png https://www.trinidadtobagowellnesstoday.com/article/906891441-rappel-le-dernier-jour-d-exercice-pour-les-bons-de-souscription-d-actions-bsa-nicox-de-juin-2024-est-le-19-juin-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T05:30:00+00:00 Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/ https://www.trinidadtobagowellnesstoday.com/article/906845683-ascentage-pharma-to-present-four-promising-preclinical-studies-demonstrating-the-potential-of-combination-therapies-at-american-association-for-cancer Trinidad & Tobago Wellness Today en PressRelease 2026-04-20T00:00:00+00:00 Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting https://ml.globenewswire.com/media/b9623a51-a13b-4b80-8152-61d5014f4a0a/small/2025-11-12-ascentage-600x600-png.png https://www.trinidadtobagowellnesstoday.com/article/906845652-sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T23:45:00+00:00 Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 https://ml.globenewswire.com/media/b29d64ff-a5d8-41ff-9d46-e0e332cc7f28/small/image001-png.png https://www.trinidadtobagowellnesstoday.com/article/906841121-monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T23:00:00+00:00 Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 https://ml.globenewswire.com/media/f8cee181-5ae9-4a02-84f5-6e35affbb72b/small/monopartherapeuticsinc-png.png https://www.trinidadtobagowellnesstoday.com/article/906832668-kimmtrak-doubles-the-likelihood-of-being-alive-at-five-years-for-first-line-hla-a-02-01-patients-with-metastatic-uveal-melanoma Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T22:00:00+00:00 KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma https://ml-eu.globenewswire.com/media/bcaafaab-2536-4b4b-899c-9913925b6e4b/small/immunocore-logo-2018.png https://www.trinidadtobagowellnesstoday.com/article/906832675-xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T22:00:00+00:00 Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://www.trinidadtobagowellnesstoday.com/article/906816139-transactions-in-zealand-pharma-shares-and-or-related-securities-by-persons-discharging-managerial-responsibilities-and-or-their-closely-associated Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T20:05:00+00:00 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://www.trinidadtobagowellnesstoday.com/article/906816100-zealand-pharma-launches-long-term-incentive-programs-for-zealand-pharma-s-board-of-directors-corporate-management-and-employees-for-2026 Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T20:00:00+00:00 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 https://ml-eu.globenewswire.com/media/31b5d115-c4a3-4dfd-b20e-d222199c4862/small/zealand-logo-1-png.png https://www.trinidadtobagowellnesstoday.com/article/906800541-revolution-medicines-to-present-updated-phase-1-clinical-data-for-zoldonrasib-in-patients-with-previously-treated-kras-g12d-non-small-cell-lung-cancer Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T18:00:00+00:00 Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/771b34d9-586d-435a-a976-ab0ab847571b/small/balanced-green-primary-logo-medium-1000px-png.png https://www.trinidadtobagowellnesstoday.com/article/906786185-molecular-partners-presents-three-posters-at-aacr-2026-with-new-preclinical-data-for-first-switch-darpin-t-cell-engager-mp0632-and-dll3-radio-darpin Trinidad & Tobago Wellness Today en PressRelease 2026-04-19T16:00:00+00:00 Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906641487-herz-p1-smart-oximeter-claims-evaluated-best-pulse-oxygen-monitor-device-on-the-market-with-clinical-grade-accuracy Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T23:25:01+00:00 Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy https://zingfast.com/wp-content/uploads/2026/04/Herz-P1-Smart-Oximeter.jpg https://www.trinidadtobagowellnesstoday.com/article/906622464-vigor-boost-gummies-claims-evaluated-the-forcevital-male-enhancement-formula-under-investigation Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T21:34:15+00:00 Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation https://zingfast.com/wp-content/uploads/2026/04/Vigor-Boost-Gummies.jpg https://www.trinidadtobagowellnesstoday.com/article/906601019-slimleaf-claims-evaluated-the-fitburn-formula-using-slim-leaf-ingredients-for-weight-loss Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T20:10:35+00:00 SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss https://zingfast.com/wp-content/uploads/2026/04/SlimLeaf.jpg https://www.trinidadtobagowellnesstoday.com/article/906577634-pliant-therapeutics-announces-presentation-of-updated-data-from-the-phase-1-trial-of-pln-101095-in-patients-with-ici-refractory-solid-tumors-at-the Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T17:31:00+00:00 Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://ml.globenewswire.com/media/e31d4c37-738e-4662-861d-675c8c564317/medium/figure-1.jpg https://www.trinidadtobagowellnesstoday.com/article/906577555-theriva-biologics-anuncia-la-pr-xima-presentaci-n-de-datos-adicionales-del-ensayo-cl-nico-virage-de-fase-2b-del-vcn-01-para-el-c-ncer-de-p-ncreas Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T17:17:08+00:00 Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026 https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://www.trinidadtobagowellnesstoday.com/article/906552980-maps-welcomes-federal-action-to-advance-science-driven-psychedelic-research-and-policy Trinidad & Tobago Wellness Today en PressRelease 2026-04-18T15:34:50+00:00 MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg